Cantor Fitzgerald Estimates Korro Bio FY2026 Earnings

Korro Bio, Inc. (NASDAQ:KRRO - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Korro Bio in a report issued on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse forecasts that the company will earn ($6.83) per share for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Korro Bio's current full-year earnings is ($9.52) per share.

Korro Bio (NASDAQ:KRRO - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($2.49) earnings per share for the quarter, beating the consensus estimate of ($2.60) by $0.11. The firm had revenue of $2.55 million during the quarter, compared to analysts' expectations of $0.13 million.

Several other brokerages also recently weighed in on KRRO. Oppenheimer lowered their target price on Korro Bio from $155.00 to $90.00 and set an "outperform" rating for the company in a research note on Tuesday, May 13th. HC Wainwright reduced their price target on shares of Korro Bio from $115.00 to $100.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Chardan Capital reiterated a "buy" rating and issued a $25.00 price target on shares of Korro Bio in a research note on Tuesday, May 13th. Finally, Royal Bank of Canada lowered their price objective on Korro Bio from $105.00 to $95.00 and set an "outperform" rating for the company in a report on Wednesday, March 19th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Korro Bio currently has an average rating of "Buy" and an average target price of $102.43.

Korro Bio Price Performance

Korro Bio stock traded down $0.44 during midday trading on Tuesday, hitting $13.54. 66,468 shares of the stock were exchanged, compared to its average volume of 110,813. Korro Bio has a 1 year low of $10.29 and a 1 year high of $98.00. The firm has a market cap of $127.15 million, a P/E ratio of -1.43 and a beta of 2.45. The company has a 50 day moving average price of $14.65 and a two-hundred day moving average price of $26.74.

Institutional Trading of Korro Bio

A number of institutional investors and hedge funds have recently modified their holdings of KRRO. Rhumbline Advisers boosted its holdings in shares of Korro Bio by 7.8% in the 4th quarter. Rhumbline Advisers now owns 9,602 shares of the company's stock valued at $366,000 after buying an additional 691 shares during the period. Balyasny Asset Management L.P. acquired a new position in Korro Bio in the fourth quarter valued at approximately $220,000. Legal & General Group Plc boosted its stake in Korro Bio by 664.1% in the fourth quarter. Legal & General Group Plc now owns 4,325 shares of the company's stock valued at $165,000 after acquiring an additional 3,759 shares during the period. Deutsche Bank AG grew its holdings in shares of Korro Bio by 29.4% during the fourth quarter. Deutsche Bank AG now owns 4,110 shares of the company's stock valued at $156,000 after purchasing an additional 935 shares during the last quarter. Finally, Wellington Management Group LLP grew its holdings in shares of Korro Bio by 11.5% during the fourth quarter. Wellington Management Group LLP now owns 14,553 shares of the company's stock valued at $554,000 after purchasing an additional 1,501 shares during the last quarter. 13.18% of the stock is owned by institutional investors and hedge funds.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).